We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Galapagos' CF Candidate Shows Potential in Phase II Study
Read MoreHide Full Article
Galapagos NV (GLPG - Free Report) announced positive top-line data from a phase II study – ALBATROSS – evaluating its cystic fibrosis transmembrane conductance (“CFTR”) corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. It led to improvements in lung function.
So far this year, Galapagos’shares have outperformed the industry. The stock has gained 41.5% compared with an increase of 1.5% registered by the industry.
The phase II study evaluated two once-daily doses – 150 mg and 300 mg – of the candidate in CF patients who have one gating mutation and an F508del mutation and were on long-term stable treatment with Vertex Pharmaceuticals Incorporated’s (VRTX - Free Report) CF drug, Kalydeco. Treatment with Kalydeco was continued during the course of the study.
The study achieved its primary objective of safety and was well tolerated in the patient population. Data also showed an improvement of 2.2% in mean percent predicted FEV1 (a measure of lung function) compared to baseline in 300 mg arm of the study.
Meanwhile, Vertex is also developing a combination therapy, tezacaftor plus Kalydeco, in similar indication.
Apart from GLPG2222, Galapagos is also developing GLPG2737, a CFTR regulator, in a phase I study and GLPG1837, a CFTR potentiator, in a phase II study in CF patients. All three candidates are being developed in partnership with AbbVie Inc. (ABBV - Free Report) . The company has a diverse pipeline with candidates being developed in several other indications including atopic dermatitis, psoriatic arthritis, uveitis and lupus membranous nephropathy among others.
Sucampo’s earnings per share estimates have increased from $1.01 to $1.12 for 2017 and from $1.06 to $1.19 for 2018 over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 15.63%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Galapagos' CF Candidate Shows Potential in Phase II Study
Galapagos NV (GLPG - Free Report) announced positive top-line data from a phase II study – ALBATROSS – evaluating its cystic fibrosis transmembrane conductance (“CFTR”) corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. It led to improvements in lung function.
So far this year, Galapagos’shares have outperformed the industry. The stock has gained 41.5% compared with an increase of 1.5% registered by the industry.
The phase II study evaluated two once-daily doses – 150 mg and 300 mg – of the candidate in CF patients who have one gating mutation and an F508del mutation and were on long-term stable treatment with Vertex Pharmaceuticals Incorporated’s (VRTX - Free Report) CF drug, Kalydeco. Treatment with Kalydeco was continued during the course of the study.
The study achieved its primary objective of safety and was well tolerated in the patient population. Data also showed an improvement of 2.2% in mean percent predicted FEV1 (a measure of lung function) compared to baseline in 300 mg arm of the study.
Meanwhile, Vertex is also developing a combination therapy, tezacaftor plus Kalydeco, in similar indication.
Apart from GLPG2222, Galapagos is also developing GLPG2737, a CFTR regulator, in a phase I study and GLPG1837, a CFTR potentiator, in a phase II study in CF patients. All three candidates are being developed in partnership with AbbVie Inc. (ABBV - Free Report) . The company has a diverse pipeline with candidates being developed in several other indications including atopic dermatitis, psoriatic arthritis, uveitis and lupus membranous nephropathy among others.
Galapagos NV Price
Galapagos NV Price | Galapagos NV Quote
Zacks Rank & Stock to Consider
Galapagos carries a Zacks Rank #3 (Hold).
Sucampo Pharmaceuticals, Inc. is a better-ranked health care stock, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings per share estimates have increased from $1.01 to $1.12 for 2017 and from $1.06 to $1.19 for 2018 over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 15.63%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>